APA (7th ed.) Citation

Ingelshed, K., Spiegelberg, D., Kannan, P., Påvénius, L., Hacheney, J., Jiang, L., . . . Sedimbi, S. K. (2022). The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy. Cancer Research Communications, 2(9), 1075. https://doi.org/10.1158/2767-9764.crc-22-0053

Chicago Style (17th ed.) Citation

Ingelshed, Katrine, et al. "The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy." Cancer Research Communications 2, no. 9 (2022): 1075. https://doi.org/10.1158/2767-9764.crc-22-0053.

MLA (9th ed.) Citation

Ingelshed, Katrine, et al. "The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy." Cancer Research Communications, vol. 2, no. 9, 2022, p. 1075, https://doi.org/10.1158/2767-9764.crc-22-0053.